Abstracts tagged "biomarkers and neuropsychiatric disorders"

Abstract Number: 779 • 2018 ACR/ARHP Annual Meeting
Cerebrospinal Fluid Biomarkers for Diagnosing Neuropsychiatric SLE: A Systematic Review and Meta-Analysis
Seyed-Foad Ahmadi¹, Golara Zahmatkesh², Masoud Majed³ and Sheetal Desai⁴, ¹Department of Medicine, University of California Irvine, Orange, CA, ²Department of Psychiatry, University of New Mexico, Albuquerque, NM, ³Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Medicine/Rheumatology, Unviersity of California, Irvine, Orange, CA
Cerebrospinal Fluid Biomarkers for Diagnosing Neuropsychiatric SLE: A Systematic Review and Meta-analysis Background/Purpose: Current guidelines recommend that in suspected neuropsychiatric SLE (NPSLE), the initial diagnostic workup…
Abstract Number: 3127 • 2015 ACR/ARHP Annual Meeting
Serologic Diagnosis of Human Neuropsychiatric Lupus Using the Immunarray ICHIP®
Chaim Putterman¹, D. Scott Batty², I.R. Cohen³, Nicole Jordan⁴, Debbie Rybak¹, Tamar Rubinstein¹, Keren Jakobi⁵, Rachel Sorek⁵, Anat Reiner-Benaim⁵, Yakov Blumenstein⁵ and Pennina Safer⁵, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²ImmunArray Inc., Richmond, VA, ³Weizmann Institute of Science, Rehovot, Israel, ⁴Montefiore Medical Center, New York, NY, ⁵ImmunArray LTD, Rehovot, Israel
Background/Purpose: Peripheral neurologic syndromes and central nervous system (CNS) manifestations are recognized as primary disease manifestations in systemic lupus erythematosus (SLE). Neuropsychiatric SLE (NPSLE) involves…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].